Abstract
Guselkumab is one of the newest biological preparations for the treatment of psoriasis and psoriatic arthritis. It is a human antibody against interleukin 23, which is a key regulatory cytokine in the pathogenesis of psoriasis and psoriatic arthritis.
Guselkumab has shown a significant and rapid onset of improvement in all domains of psoriatic arthritis with a favorable safety profile.